Literature DB >> 7469101

Pharmacokinetics of intravenous morphine in patients anesthetized with enflurane-nitrous oxide.

M R Murphy, C C Hug.   

Abstract

Morphine is used as an anesthetic supplement. Its disposition in surgical patients under enflurane-nitrous oxide anesthesia has not been determined. Available data on morphine concentrations in plasma after equivalent intravenous doses are conflicting, possibly as a result of varying degrees of specificity of the analytical methods for the unchanged, pharmacologically active form of the drug. This study determined the pharmacokinetics of morphine (0.05, 0.1, 0.14, or 0.2 mg/kg) injected intravenously in 10 surgical patients anesthetized with enflurane-N2O-O2. Arterial plasma was analyzed for unchanged morphine and conjugated morphine. Specificity of the analytical procedure for unchanged morphine was achieved by the combination of solvent extraction and radioimmunoassay techniques. Kinetic indices were derived by nonlinear least-squares analysis of log concentration (ng/ml) vs. time relationships. Morphine disposition was independent of dose in this fourfold range and was best described by a three-compartment model with a mean elimination half-time (t1/2 beta) of 104 +/- 5 min. The apparent volumes of distribution (Vd) and of the central compartment (V1) were 3.4 +/- 0.2 and 0.13 +/- 0.02 l/kg, respectively, while the clearance (ClB) was 23 +/- 1 ml x min-1 x kg-1. Extraction of morphine by the liver appeared to be complete. Conjugated morphine was eliminated from plasma with a t1/2 beta of 169 +/- 15 min. The ultimate elimination of morphine from the body was dependent upon its uptake from slowly perfused peripheral tissues, K10 greater than k31(P less than .001).

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7469101     DOI: 10.1097/00000542-198103000-00003

Source DB:  PubMed          Journal:  Anesthesiology        ISSN: 0003-3022            Impact factor:   7.892


  12 in total

1.  Determination of the distribution volume that can be used to calculate the intravenous loading dose.

Authors:  D R Wada; D R Drover; H J Lemmens
Journal:  Clin Pharmacokinet       Date:  1998-07       Impact factor: 6.447

2.  Hepatic extraction of morphine is impaired in cirrhosis.

Authors:  B Crotty; K J Watson; P V Desmond; M L Mashford; L J Wood; J Colman; F J Dudley
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

3.  Profound reduction in morphine clearance and liver blood flow in shock.

Authors:  M S Macnab; D J Macrae; E Guy; I S Grant; J Feely
Journal:  Intensive Care Med       Date:  1986       Impact factor: 17.440

Review 4.  Intravenous anaesthetic agents. Pharmacokinetic-pharmacodynamic relationships.

Authors:  B N Swerdlow; F O Holley
Journal:  Clin Pharmacokinet       Date:  1987-02       Impact factor: 6.447

5.  Bibliography for the control of anxiety, fear and pain in dentistry.

Authors:  G L McAlister; C L Richardson
Journal:  Anesth Prog       Date:  1982 Nov-Dec

6.  Morphine and morphine-6-glucuronide in the plasma and cerebrospinal fluid of children.

Authors:  R D Hain; A Hardcastle; C R Pinkerton; G W Aherne
Journal:  Br J Clin Pharmacol       Date:  1999-07       Impact factor: 4.335

7.  Pharmacokinetics of nicomorphine and its metabolites in man after epidural administration.

Authors:  P M Koopman-Kimenai; T B Vree; M A Hasenbos; E W Weber; C P Verweij-Van Wissen; L H Booij
Journal:  Pharm Weekbl Sci       Date:  1991-06-21

Review 8.  High-dose morphine and methadone in cancer patients. Clinical pharmacokinetic considerations of oral treatment.

Authors:  J Säwe
Journal:  Clin Pharmacokinet       Date:  1986 Mar-Apr       Impact factor: 6.447

Review 9.  Patient-controlled analgesia. Pharmacokinetic and therapeutic considerations.

Authors:  H F Hill; L E Mather
Journal:  Clin Pharmacokinet       Date:  1993-02       Impact factor: 6.447

10.  Evaluation of the accuracy of a pharmacokinetically-based patient-controlled analgesia system.

Authors:  H Hill; A Mackie; B Coda; R Schaffer; R Jacobson; C Benedetti
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.